Literature DB >> 18259859

Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle.

Anete Curte Ferraz1, Francesca Matheussi, Raphael Escorsim Szawka, Vanessa Rizelio, Ana Márcia Delattre, Paula Rigon, Erica do Espírito Santo Hermel, Léder Leal Xavier, Matilde Achaval, Janete A Anselmo-Franci.   

Abstract

Studies involving estrogen treatment of ovariectomized rats or mice have attributed to this hormone a neuroprotective effect on the substantia nigra pars compacta (SNpc) neurons. We investigated the effect of estradiol replacement in ovariectomized rats on the survival of dopaminergic mesencephalic cell and the integrity of their projections to the striatum after microinjections of 1 microg of 6-hydroxydopamine (6-OHDA) into the right SNpc or medial forebrain bundle (MFB). Estradiol replacement did not prevent the reduction either in the striatal concentrations of DA and metabolites or in the number of nigrostriatal dopaminergic neurons following lesion with 1 microg of 6-OHDA into the SNpc. Nevertheless, estradiol treatment reduced the decrease in striatal DA following injection of 1 microg of 6-OHDA into the MFB. Results suggest therefore that estrogen protect nigrostriatal dopaminergic neurons against a 6-OHDA injury to the MFB but not the SNpc. This may be due to the distinct degree of lesions promoted in these different rat models of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18259859     DOI: 10.1007/s11064-007-9575-7

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  40 in total

1.  The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry.

Authors:  P Damier; E C Hirsch; Y Agid; A M Graybiel
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

Review 2.  From clinical evidence to molecular mechanisms underlying neuroprotection afforded by estrogens.

Authors:  Diana Amantea; Rossella Russo; Giacinto Bagetta; Maria Tiziana Corasaniti
Journal:  Pharmacol Res       Date:  2005-08       Impact factor: 7.658

Review 3.  Mechanistic approaches to Parkinson's disease pathogenesis.

Authors:  Ranjita Betarbet; Todd B Sherer; Donato A Di Monte; J Timothy Greenamyre
Journal:  Brain Pathol       Date:  2002-10       Impact factor: 6.508

Review 4.  Estrogen as a neuroprotectant in stroke.

Authors:  P D Hurn; I M Macrae
Journal:  J Cereb Blood Flow Metab       Date:  2000-04       Impact factor: 6.200

5.  Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.

Authors:  Ruxandra Iancu; Paul Mohapel; Patrik Brundin; Gesine Paul
Journal:  Behav Brain Res       Date:  2005-07-01       Impact factor: 3.332

6.  Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females.

Authors:  H E Murray; A V Pillai; S R McArthur; N Razvi; K P Datla; D T Dexter; G E Gillies
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

7.  Failure of estrogen to protect the substantia nigra pars compacta of female rats from lesion induced by 6-hydroxydopamine.

Authors:  Anete Curte Ferraz; Léder Leal Xavier; Sílvia Hernandes; Martha Sulzbach; Giordano Gubert Viola; Janete A Anselmo-Franci; Matilde Achaval; Claudio Da Cunha
Journal:  Brain Res       Date:  2003-10-03       Impact factor: 3.252

8.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

9.  Unique responses to mitochondrial complex I inhibition in tuberoinfundibular dopamine neurons may impart resistance to toxic insult.

Authors:  B Behrouz; R E Drolet; Z A Sayed; K J Lookingland; J L Goudreau
Journal:  Neuroscience       Date:  2007-06-20       Impact factor: 3.590

10.  Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease.

Authors:  G M Halliday; D A McRitchie; H Cartwright; R Pamphlett; M A Hely; J G Morris
Journal:  J Clin Neurosci       Date:  1996-01       Impact factor: 1.961

View more
  9 in total

1.  Effect of different doses of estrogen on the nigrostriatal dopaminergic system in two 6-hydroxydopamine-induced lesion models of Parkinson's disease.

Authors:  Marcela Ferreira Cordellini; Giovana Piazzetta; Karin Cristine Pinto; Ana Márcia Delattre; Francesca Matheussi; Ruither O G Carolino; Raphael Escorsim Szawka; Janete A Anselmo-Franci; Anete Curte Ferraz
Journal:  Neurochem Res       Date:  2011-02-24       Impact factor: 3.996

2.  Antidepressant Effects of Ketamine Are Not Related to ¹⁸F-FDG Metabolism or Tyrosine Hydroxylase Immunoreactivity in the Ventral Tegmental Area of Wistar Rats.

Authors:  Pedro Porto Alegre Baptista; Lisiani Saur; Pamela Bambrilla Bagatini; Samuel Greggio; Gianina Teribele Venturin; Sabrina Pereira Vaz; Kelly Dos Reis Ferreira; Juliana Silva Junqueira; Diogo Rizzato Lara; Jaderson Costa DaCosta; Cristina Maria Moriguchi Jeckel; Régis Gemerasca Mestriner; Léder Leal Xavier
Journal:  Neurochem Res       Date:  2015-04-17       Impact factor: 3.996

Review 3.  Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.

Authors:  Glenda E Gillies; Simon McArthur
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

4.  Oestrogen receptors enhance dopamine neurone survival in rat midbrain.

Authors:  M L Johnson; C C Ho; A E Day; Q D Walker; R Francis; C M Kuhn
Journal:  J Neuroendocrinol       Date:  2010-01-27       Impact factor: 3.627

5.  MPTP Neurotoxicity and Testosterone Induce Dendritic Remodeling of Striatal Medium Spiny Neurons in the C57Bl/6 Mouse.

Authors:  Eleni Antzoulatos; Michael W Jakowec; Giselle M Petzinger; Ruth I Wood
Journal:  Parkinsons Dis       Date:  2011-06-08

6.  Peripheral vs. Central Sex Steroid Hormones in Experimental Parkinson's Disease.

Authors:  Simon McArthur; Glenda E Gillies
Journal:  Front Endocrinol (Lausanne)       Date:  2011-11-30       Impact factor: 5.555

Review 7.  Sex differences in Parkinson's disease.

Authors:  Glenda E Gillies; Ilse S Pienaar; Shiv Vohra; Zahi Qamhawi
Journal:  Front Neuroendocrinol       Date:  2014-03-04       Impact factor: 8.606

Review 8.  Enduring, Sexually Dimorphic Impact of In Utero Exposure to Elevated Levels of Glucocorticoids on Midbrain Dopaminergic Populations.

Authors:  Glenda E Gillies; Kanwar Virdee; Ilse Pienaar; Felwah Al-Zaid; Jeffrey W Dalley
Journal:  Brain Sci       Date:  2016-12-30

9.  Neuroprotective effect of sodium alginate against chromium-induced brain damage in rats.

Authors:  Eman M Saleh; Germine M Hamdy; Rasha E Hassan
Journal:  PLoS One       Date:  2022-04-14       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.